Waterfront Wealth Inc. Buys 15,748 Shares of Sanofi (NASDAQ:SNY)

Waterfront Wealth Inc. raised its stake in Sanofi (NASDAQ:SNY - Free Report) by 46.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 49,958 shares of the company's stock after acquiring an additional 15,748 shares during the quarter. Waterfront Wealth Inc.'s holdings in Sanofi were worth $2,409,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in SNY. Synergy Asset Management LLC purchased a new stake in Sanofi in the 4th quarter worth about $25,000. McClarren Financial Advisors Inc. increased its stake in shares of Sanofi by 952.6% in the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company's stock worth $28,000 after purchasing an additional 543 shares in the last quarter. Concord Wealth Partners raised its position in shares of Sanofi by 157.8% in the third quarter. Concord Wealth Partners now owns 593 shares of the company's stock valued at $34,000 after purchasing an additional 363 shares during the period. Fortitude Family Office LLC lifted its stake in shares of Sanofi by 708.6% during the 3rd quarter. Fortitude Family Office LLC now owns 752 shares of the company's stock valued at $43,000 after buying an additional 659 shares in the last quarter. Finally, Sunbelt Securities Inc. boosted its holdings in Sanofi by 72.1% in the 3rd quarter. Sunbelt Securities Inc. now owns 747 shares of the company's stock worth $43,000 after buying an additional 313 shares during the period. 14.04% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have issued reports on SNY shares. Sanford C. Bernstein raised shares of Sanofi to a "strong-buy" rating in a report on Thursday, January 30th. StockNews.com lowered Sanofi from a "buy" rating to a "hold" rating in a research note on Thursday, December 12th. Finally, Deutsche Bank Aktiengesellschaft upgraded Sanofi from a "sell" rating to a "hold" rating in a research note on Thursday, January 30th. Two research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $60.00.

Sanofi Price Performance

Shares of SNY traded up $1.14 during mid-day trading on Tuesday, reaching $54.89. 2,338,818 shares of the stock traded hands, compared to its average volume of 2,419,275. The company has a market cap of $139.30 billion, a price-to-earnings ratio of 22.04, a price-to-earnings-growth ratio of 1.01 and a beta of 0.57. Sanofi has a 1 year low of $45.22 and a 1 year high of $58.97. The firm has a fifty day moving average price of $51.10 and a 200 day moving average price of $52.55. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. As a group, equities research analysts predict that Sanofi will post 4.36 earnings per share for the current year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.